Ultragenyx Pharma (RARE) Tops Q4 EPS by 6c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. FIX
9. TSCO
10. BE

Go back to Ultragenyx Pharma (RARE) Tops Q4 EPS by 6c, Revenues Beat

Ultragenyx Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Update

February 19, 2019 4:01 PM EST

NOVATO, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results and corporate update for the quarter and full year ended December 31, 2018.

This last year was important for Ultragenyx as we successfully launched two therapies internationally and validated clinical data from our gene therapy platform, said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. In 2019 we look forward to expanding the global commercial reach of our... More